SeraNovo BV based in Leiden, The Netherlands, entered a License Agreement with Équilibre BioPharmaceuticals Corp. in New York, a biopharmaceutical company developing small molecules in the field of neuroscience. Under the agreement, the companies will expand their existing collaboration and jointly develop a breakthrough product.   Niall Hodgins, Chief Executive Officer of SeraNovo said, “We are thrilled to enter into this license agreement with Équilibre and progress another poorly water solu...